

1 **Intravenous iron therapy with ferric carboxymaltose results in a rapid and sustained rise in**  
2 **myocardial iron content through a non-canonical pathway: a translational study**

3

4 Vera-Aviles M<sup>1\*</sup>, Kabir S<sup>1\*</sup>, Shah A<sup>2\*</sup>, Polzella P<sup>3\*</sup>, Lim Y<sup>1</sup>, Buckley P<sup>1</sup>, Ball C<sup>1</sup>, Swinkels D<sup>4</sup>, Matlung H<sup>5</sup>,  
5 Blans C<sup>5</sup>, Holdship P<sup>6</sup>, Nugent J<sup>7</sup>, Andreson E<sup>7</sup>, Desborough M<sup>3</sup>, Piechnik S<sup>8</sup>, Ferreira V<sup>8</sup>, Lakhali-  
6 Littleton S<sup>1</sup>

7 <sup>1</sup> Department of Physiology, Anatomy & Genetics, University of Oxford

8 <sup>2</sup> Nuffield Department of Clinical Neurosciences, University of Oxford

9 <sup>3</sup> Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust.

10 <sup>4</sup> Iron Expertise Centre, Department of Laboratory Medicine, Radboud university medical centre,  
11 Nijmegen, Netherlands & Iron Expertise Centre, Sanquin Blood Bank, Amsterdam, Netherlands

12 <sup>5</sup> Sanquin Diagnostic Services, Amsterdam, Netherlands & Sanquin Research and Landsteiner  
13 Laboratory, Amsterdam, Netherlands

14 <sup>6</sup> Department of Earth Sciences, University of Oxford

15 <sup>7</sup> Department of Chemistry, University of Oxford

16 <sup>8</sup> Oxford Centre for Clinical Magnetic Resonance Research (OCMR), University of Oxford

17 \*Equal contribution

18

19 Correspondence: Prof S Lakhali-Littleton, Department of Physiology, Anatomy & Genetics,  
20 Sherrington Building, Parks Road, Oxford, OX1 3PT [samira.lakhali-littleton@dpag.ox.ac.uk](mailto:samira.lakhali-littleton@dpag.ox.ac.uk)

21

22 **ABSTRACT**

23 **Background and Aims**

24 Intravenous iron therapies contain iron-carbohydrate complexes, designed to ensure iron becomes  
25 bioavailable via the intermediary of spleen and liver reticuloendothelial macrophages. How other  
26 tissues obtain and handle this iron remains unknown. This study addresses this question in the  
27 context of the heart.

28 **Methods**

29 A prospective observational study was conducted in 12 patients receiving ferric carboxymaltose  
30 (FCM) for iron deficiency. Myocardial, spleen and liver magnetic resonance relaxation times, and  
31 plasma iron markers were collected longitudinally. To examine the handling of iron taken up by the  
32 myocardium, intracellular labile iron pool (LIP) was imaged in FCM-treated mice and cells.

33 **Results**

34 In patients, myocardial relaxation time T1 dropped maximally 3hrs post FCM, remaining low 42 days  
35 later, while splenic T1 dropped maximally at 14 days, recovering by 42 days. In plasma, non-  
36 transferrin bound iron (NTBI) peaked at 3hrs, while ferritin peaked at 14 days. Changes in liver T1  
37 diverged amongst patients. In mice, myocardial LIP rose 1h and remained elevated 42 days after  
38 FCM. In cardiomyocytes, FCM exposure raised LIP rapidly. This was prevented by inhibitors of NTBI  
39 transporters T-type and L-Type calcium channels and divalent metal transporter 1.

40 **Conclusions**

41 Intravenous iron therapy with FCM delivers iron to the myocardium rapidly through NTBI  
42 transporters, independently of reticuloendothelial macrophages. This iron remains labile for weeks,  
43 reflecting the myocardium's limited iron storage capacity. These findings challenge current notions  
44 of how the heart obtains iron from these therapies and highlight the potential for long-term dosing  
45 to cause cumulative iron build-up in the heart.

46 **KEYWORDS**

47 Intravenous iron therapy

48 Myocardium

49 Labile iron

50 Non-transferrin bound iron

51 Ferric carboxymaltose

52 Magnetic resonance

53

## 54 **TRANSLATIONAL PERSPECTIVE**

- 55 • Many patients now receive long-term IV iron therapy. The finding that a single standard  
56 dose of IV iron causes a sustained rise in myocardial iron underscores the risk for cumulative  
57 build-up to occur with multiple doses. Magnetic resonance monitoring of myocardial iron  
58 may be required to safeguard against progression towards pathological myocardial iron  
59 overload in these patients.
- 60 • Plasma ferritin levels reflect the iron content of reticuloendothelial macrophages. The  
61 finding that myocardial iron elevation following IV iron therapy is independent from  
62 reticuloendothelial macrophages highlights the limitations of using plasma ferritin cut-offs to  
63 safeguard against the risk of tissue iron overload.

## 65 **INTRODUCTION**

66 Iron deficiency ID is the commonest nutritional deficiency worldwide and is associated with adverse  
67 outcomes in a broad range of settings<sup>1-12</sup>. Thus, tackling ID efficiently and safely holds the potential  
68 to deliver cross-cutting benefits to large numbers of patients. ID has been traditionally treated with  
69 oral iron supplements, which replenish iron incrementally over weeks by delivering ~100mg doses  
70 into the gut lumen, of which typically 10 to 22% is absorbed into the circulation<sup>13</sup>. Oral iron's  
71 gastrointestinal side effects, poor compliance and limited absorption in inflammatory settings have  
72 fuelled a gradual shift towards intravenous iron therapies<sup>14-18</sup>. These can deliver up to 2000mg of  
73 iron into the circulation at once. To minimise the otherwise toxic effects of free iron, the iron in IV  
74 iron therapies is contained within carbohydrate complexes<sup>18</sup>. These are designed for targeted uptake  
75 by macrophages of the reticuloendothelial system, in the spleen and to a lesser extent in the liver<sup>18-</sup>  
76 <sup>20</sup>. According to the consensus canonical pathway of IV iron metabolism, the iron-carbohydrate  
77 complex is degraded within the lysosome, iron freed, exported into the circulation and loaded onto  
78 the plasma iron chaperone transferrin<sup>18-20</sup>. The iron made bioavailable through this pathway is  
79 considered safe, because the transferrin-bound iron is non-reactive and only taken up by tissues  
80 according to their needs. Indeed, surface expression of transferrin receptor (TfR) is coupled to  
81 cellular iron need, because its translation is controlled by the iron homeostatic proteins Iron  
82 Regulatory Proteins (IRPs)<sup>21</sup>. Inside cells, labile iron is quickly made non-reactive through storage into  
83 ferritin, the translation of which is also controlled by IRPs<sup>21</sup>. Because plasma ferritin derives primarily  
84 from macrophages, uptake of iron-carbohydrate complexes by reticuloendothelial macrophages is  
85 closely followed by a rise in plasma ferritin<sup>22-23</sup>.

86 Pharmacokinetic studies have reported a rapid rise in plasma non-transferrin bound iron (NTBI)  
87 following treatment with intravenous iron, indicating that some iron is released from the  
88 carbohydrate complex directly into the circulation<sup>24</sup>. What remains unknown is whether this NTBI is  
89 taken up by tissues, and the extent to which such uptake contributes to the ultimate rise in tissue  
90 iron content resulting from intravenous iron therapy. This is an important question because, unlike  
91 transferrin-bound iron, NTBI enters cells via non-canonical pathways that are not coupled to cellular  
92 iron need<sup>25</sup>. Because NTBI transporters are not regulated by IRPs, they continue to take up iron  
93 despite excess cellular labile iron<sup>25</sup>. The heart is particularly prone to NTBI uptake due to abundant  
94 expression of certain NTBI transporters including L-type and T-type calcium channels (LTCCs, TTCCs)  
95 and divalent metal transporter 1 (DMT1)<sup>26,27</sup>. This, together with the heart's relatively limited  
96 capacity to store labile iron into ferritin explain why iron overload cardiomyopathy is a frequent and  
97 fatal complication in hemochromatosis and  $\beta$ -thalassaemia<sup>28-30</sup>.

98 Tissue iron uptake can be assessed non-invasively by magnetic resonance (MR) because the  
99 ferromagnetic properties of iron influence certain MR tissue characteristics, in particular relaxation  
100 times T1, T2, and T2\*<sup>31</sup>. Furthermore, the handling of iron taken up into tissues can be assessed  
101 through reporter systems that rely on labile iron reactivity<sup>32</sup>. Using these approaches, the objective  
102 of the current study is to investigate myocardial uptake and handling of iron following intravenous  
103 iron therapy with the most widely used formulation ferric carboxymaltose (FCM, Ferinject®).

## 104 **METHODS**

105 This report was prepared according to STROBE and ARRIVE guidelines.

### 106 **Clinical Study Design**

107 Study of Tissue Iron Uptake in Iron-deficient patients following intravenous iron therapy (STUDY) is  
108 an investigator-initiated, prospective, observational study conducted at one UK site, sponsored by  
109 the University of Oxford. The full study protocol is available in Supplemental File 3. The trial protocol  
110 and amendments were approved by a NHS ethics committee in the UK (North West - Liverpool  
111 Central Research Ethics Committee Ref: 22/NW/0172), and the Health Research Authority. The study  
112 was registered prospectively on the ISRCTN registry (ISRCTN15770553) and clinicaltrials.gov  
113 (NCT05609318). The sample size of 12 participants was not arrived at statistically, due to lack of  
114 previous information on the magnitude of acute effects of FCM on T1/T2/T2\* values. Instead, the  
115 sample size of 12 was selected based on a previous exploratory study of MRI imaging following  
116 intravenous infusion with ultrasmall superparamagnetic particles of iron oxide (USPIO), which used  
117 sample sizes of 5-12 participants per group<sup>33</sup>.

### 118 **Patients**

119 Patients were recruited through the Iron Deficiency Management Service, part of the Oxford  
120 University Hospitals NHS Foundation Trust (OUHFT). Patients, aged 18 years or above, scheduled to  
121 receive intravenous iron therapy as per standard clinical care for correction of iron deficiency  
122 (ferritin less than 100mcg/L and/or transferrin saturation less than 20%) with or without anaemia  
123 (haemoglobin less than 120g/L for women and less than 130g/L for men) were invited to participate.  
124 All eligible patients identified during the screening period were contacted. Following written  
125 informed consent, patients were screened for exclusion criteria, which were any of the following:  
126 any MRI incompatible implants, pregnant or lactating participants, acute decompensated heart  
127 failure, unstable clinical status, any other medical conditions which would influence the reliability of  
128 the study results as determined by the investigators, any other contraindication to MRI. The full list  
129 of inclusion and exclusion criteria is provided within the study protocol in Supplemental File.

### 130 **Study Procedures**

131 A flow chart outlining study procedures is shown in Appendix A of study protocol in Supplemental  
132 File.

133 The full CMR protocol (including the standard Siemens printout) and mapping methods are provided  
134 in supplemental File.

135 FCM solution (Ferinject® [FCM], Vifor Pharma, Glattbrugg, Switzerland) was given as a 20-mL  
136 intravenous infusion (equivalent to 1000 mg of iron) diluted in a sterile saline solution (0.9% wt/vol  
137 NaCl) and administered over 15 minutes. Participants were closely monitored for signs of  
138 hypersensitivity during the infusion and for at least 30 min after the treatment, as per standard  
139 clinical care.

## 140 **Study Outcomes**

141 Primary outcome- Changes from baseline in multi-organ magnetic resonance relaxation times T1, T2  
142 and T2\* for each participant.

143 Secondary outcome- Change from baseline in plasma iron indices: iron, ferritin , transferrin  
144 saturation Tsat, non-transferrin bound iron NTBI, and serum levels of lipid peroxidation marker  
145 malondialdehyde MDA

## 146 **Mice**

147 All animal procedures were compliant with the UK Home Office Animals (Scientific Procedures) Act  
148 1986 (licence# P84F13B1B) and approved by the University of Oxford Medical Sciences Division  
149 Ethical Review Committee. Bioluminescence studies used B6;FVB-Ptprca Tg(CAG-luc,-  
150 GFP)L2G85Chco Thy1a/J mice (JAX strain #025854), which harbour the firefly luciferase transgene  
151 under control of CAG promoter; composed of human cytomegalovirus immediate early promoter  
152 enhancer with chicken beta-actin/rabbit beta-globin hybrid promoter. These mice have previously  
153 been characterised as having bioluminescence in the heart, spleen, muscle, pancreas, skin, thymus  
154 and bone marrow, but not in mature erythrocytes<sup>36</sup>. Mice were housed under standard conditions  
155 in individually-ventilated cages with enrichment at a density of 2-4 animals per cage. A priori  
156 humane endpoints were weight loss  $\geq 15\%$ , or signs of ill health (hunched posture and reduced  
157 activity) that did not resolve within 24 hours. Each animal represents an experimental unit. All  
158 animals were given an identifier code, to allow blinding during the conduct and analysis of  
159 experiments. Power calculations were not used due to lack of previous data on myocardial LIP.

## 160 **Manipulation of iron status in mice**

161 Mice heterozygous for luciferase transgene were randomly assigned to a standard iron-replete diet  
162 containing 200 ppm iron (n=22), or an iron-deficient diet containing 5 ppm iron (n=25) (Teklad  
163 TD.99397), which were provided for 6 weeks.

164 Within each dietary group, mice were then randomly assigned to receive a 100ul injection via the tail  
165 vein of either saline (n=11 for iron-replete diet, n=12 for iron-deficient diet) or iron as ferric  
166 carboxymaltose (Ferinject® [FCM], Vifor Pharma, Glattbrugg, Switzerland) at 15mg/kg (n=11 for iron-  
167 replete group, n=13 for iron-deficient group). Mice were used for bioluminescence imaging either 1  
168 hour or 42 days post infusion. To minimise any potential confounding effects of age and sex, all  
169 animals entered the diary protocol at 6 weeks of age, and block randomisation was used to ensure  
170 balanced numbers of males and females in each group. Randomisation into diets and treatments  
171 was carried out using the Rand() function in excel.

## 172 **Labile iron imaging in murine hearts**

173 Bioluminescence studies used the iron-caged luciferin described previously<sup>32</sup>.

174 Mice were anaesthetised using 2% isoflurane in O<sub>2</sub>, and injected via the tail vein with 25nmoles of  
175 iron-caged luciferin (ICL-1) dissolved in 100ul saline. One minute later, the chest cavity was opened,  
176 and the heart immediately surgically excised, washed in ice-cold PBS to remove any blood clots, and  
177 placed on a petri dish within the IVIS Lumina system. Bioluminescence imaging was performed in an  
178 IVIS LUMINA II system, with small binning and F stop 1 settings. Bioluminescence signal was  
179 collected for at least 2 minutes, with auto settings. Luminescence data were extracted using Living  
180 Image Software4.7.3. First, a non-luminescence photograph was used to generate ROIs, by manually  
181 drawing around the outline of each heart (excluding atria). ROIs corresponding to individual hearts

182 were automatically propagated onto the luminescence sequence, and average radiance extracted  
183 from each ROI as p/s/cm<sup>2</sup>/sr (photons, per second, per square cm, per steradian). The mean of the  
184 average radiance values acquired over in the first two minutes were calculated for each heart.

185 Following removal of the heart, blood was immediately collected from the chest cavity for Hb  
186 measurement and preparation of serum. Spleens and livers were also removed, washed in ice-cold  
187 PBS before snap-freezing for quantitation of total iron content.

188 No animals were lost to humane endpoints. However, some animals did not undergo myocardial LIP  
189 imaging due to failure to infuse ICL-1 intravenously prior to imaging. Their spleens and livers were  
190 still harvested for direct iron quantitation.

### 191 **Iron quantitation in murine tissues**

192 Snap-frozen livers and spleens were crushed on liquid nitrogen, and a minimum of 5mg digested in  
193 nitric acid using a CEM microwave system. Elemental component analysis was carried out using  
194 induced couple plasma mass spectrometry ICP-MS as per previous studies<sup>37</sup>. Values are normalised  
195 to tissue weight.

### 196 **Cardiac myocytes**

197 For in-vitro bioluminescence studies, the rat cardiac myocyte cell line H9C2 (ATCC CRL1446, cardiac  
198 myoblasts from rat) was transfected with Firefly Luciferase-eGFP Lentivirus (Tetubio, product  
199 reference #14979980) and positive selection was maintained by inclusion of Geneticin in growth  
200 media. Transfected cells were maintained in complete Dulbecco's Modified Eagle's Medium (DMEM)  
201 growth medium, supplemented with 10% fetal bovine serum (FBS) in standard tissue culture  
202 conditions.

### 203 **Labile iron imaging in cultured cardiac myocytes**

204 Cells were plated in complete media in opaque 96 well plates at 50000cells/well overnight. To  
205 eliminate any confounding effects of existing iron in FBS, growth media were changed to FBS-free  
206 DMEM media two hours before treatment with sterile saline or FCM, still in FBS-free media. The  
207 amount of FCM added to the FBS-free media were determined as follows; as the standard human  
208 FCM dose is 15mg iron/Kg, and the average plasma volume in humans is 60ml/Kg, the concentration  
209 of iron delivered to human plasma following a standard FCM dose is 0.25mg/mL. Thus FCM was  
210 added to the FBS-free growth media at a concentration of 0.25mg iron/mL to mimic the standard  
211 human dose.

212 Prior to imaging, saline and FCM-containing media were removed, cells washed with PBS, then ICL-1  
213 added at 100uM to each well, and plates imaged immediately in an IVIS LUMINA II system, using the  
214 sequence settings described above. Luminescence data were extracted using Living Image Software,  
215 using the standard 12X8 grid ROI setting.

### 216 **Haematological and iron parameters**

217 Peripheral venous blood from participants was collected into lithium heparin tubes. Some blood was  
218 subject to haematological analysis for a full blood count using an ABX Pentra 60 system and the  
219 remainder was used to extract plasma by spinning at 2500g for 10min at 4C. Plasma samples were  
220 immediately stored at -80C for further analysis.

221 Haemoglobin in mice was recorded from fresh blood using the HemoCue Hb 201+ system. To extract  
222 serum, blood was allowed to clot at room temperature for 2 hours, before spinning at 4000g for 10  
223 min. Serum was stored at -80C for further analysis.

224 Iron, serum ferritin, transferrin levels were determined in human plasma and mouse serum using the  
225 ABX-Pentra C400 system (Horiba). Transferrin saturation was calculated using iron and transferrin  
226 concentrations. NTBI measurements were carried out by Sanquin Diagnostic Services (Amsterdam)  
227 as described previously<sup>38</sup>. It was not possible to obtain data on serum iron and NTBI from some  
228 animals due to the amount of serum collected not meeting the minimum volume requirements for  
229 the respective assays.

230 MDA levels were measured in plasma or serum using Lipid Peroxidation kit Abcam (ab233471)  
231 according to the manufacturer's instructions.

### 232 **Statistical analysis**

233 Data in figures are shown as mean  $\pm$  standard error of the mean  $\pm$  S.E.M. In-text values are reported  
234 as mean  $\pm$  STDEV.

235 Normality and equal variance were tested using the Shapiro-Wilk test and Levene test respectively.  
236 Pairwise comparisons were drawn using 2-tailed, unpaired t test (for sample size  $n \geq 5$ ), or Mann-  
237 Whitney test (for sample size  $< 5$ ). Multiple group comparisons were drawn using a 1-way or 2-way  
238 ANOVA followed by Dunnett's post hoc test. Longitudinal repeated measure data in patients were  
239 analysed using mixed effects analysis to account for missing data, with Dunnett's multiple  
240 comparison test. P value of less than 0.05 was considered statistically significant. Analysis was  
241 carried out using GraphPad PRISM.10

## 242 **RESULTS**

### 243 **Ferric carboxymaltose treatment in patients results in rapid and sustained rise in myocardial iron**

244 Between October 18<sup>th</sup> 2022 and July 31<sup>st</sup> 2023, 54 patients were screened for eligibility, of whom 13  
245 were recruited, and 12 completed the study (Figure 1). Patient demographics and baseline  
246 characteristics are shown in Table 1.

247 **Table 1- Patient demographics and baseline characteristics (n=12)**

Characteristic	Value
Age (years), median (IQR), [Range]	44 (12) [27-69]
Sex, n (%)	
Female / Male	11 (91)/ 1 (9)
Weight (kg), mean (SD)	71.2 (13.7)
BMI (kg/m <sup>2</sup> ), median (IQR)	27.2 (5.7)
Ethnicity, n (%)	
White	6 (50)
South Asian	4 (33)
Black	1 (17)
Mixed	0 (0)
Other	1 (17)
Reason for referral n, (%)	
Heavy menstrual bleeding	8 (66.8%)
Abnormal uterine bleeding (e.g. fibroids)	1 (8.3%)
Rectal bleeding	1 (8.3%)



IDA of unclear aetiology	2 (16.6%)
<b>Previous IV iron infusions, n (%)</b>	
None	9 (75)
One prior infusion	3 (25)
<b>Relevant comorbidities, n (%)</b>	
Ischaemic heart disease	0 (0)
Chronic respiratory disease (asthma, COPD)	0 (0)
<b>Laboratory iron parameters at referral (Normal range), median (IQR)</b>	
Haemoglobin (120- 170), g/l	106 (12)
Ferritin (10 – 300), mcg/l	7.4 (10.1)
Tsat (16 – 50), %	7 (3)

248 BMI, Body Mass Index; COPD, Chronic Obstructive Pulmonary Disease; IDA, Iron deficiency anaemia;  
249 IQR, Interquartile range; IV, intravenous; SD, Standard deviation; Tsat, Transferrin saturation

250 To assess the short and long-term impact of FCM on myocardial iron, participants were scanned  
251 immediately prior to infusion (0h), then three hours (3h), 14 days and 42 days post infusion (Figure  
252 2A). At 3h post infusion, myocardial T1 dropped in 11/12 participants, with a mean change ( $\Delta T1$ ) of -  
253  $35.35 \pm 26.88$ ms ( $p=0.0008$ ). At 14 days and 42 days post infusion, myocardial T1 was still lower than  
254 0h values, with a change of  $-26.76 \pm 32.93$ ms ( $p=0.0255$ ) and  $-28.45 \pm 20.33$ ms ( $p=0.008$ ) respectively.  
255 Importantly,  $\Delta T1$  values at days 14 and 42 were not significantly different from those at 3h post  
256 infusion ( $p=0.709$  and  $0.775$  respectively) (figure 2B). Thus, a single standard dose of FCM in patients  
257 with iron deficiency raises myocardial iron rapidly and maximally within 3 hours, and this rise is  
258 sustained for at least 42 days post infusion.

259 To understand the pathways underlying the rise in myocardial iron, we also assessed changes in  
260 spleen and liver iron, where reticuloendothelial macrophages reside. Splenic T1 dropped in all  
261 participants at 3hrs post infusion, with a mean drop ( $\Delta T1$ ) of  $-39.7 \pm 36.2$ ms ( $p<0.0001$ ). However  
262 maximal drop of  $-193.9 \pm 30.59$ ms was only seen at 14 days ( $p<0.0001$ ). By 42 days post infusion, the  
263 mean drop  $\Delta T1$  was  $-137 \pm 33.68$ ms ( $p<0.0001$ ). Between days 14 and 42, there was a statistically  
264 significant recovery in  $\Delta T1$  values ( $p=0.0004$ ) (Figure 2C). Thus, after a single standard dose of FCM in  
265 patients with iron deficiency, spleen iron begins to rise within 3 hours, but rises maximally at 14  
266 days, and is declining by 42 days..

267 Next, we assessed T1 changes in the liver. At 3h post infusion, liver T1 dropped in 11/12 participants.  
268 The mean  $\Delta T1$  was  $-23 \pm 19.9$ ms ( $p=0.0168$ ). By 14 days and 42 days post infusion, liver  $\Delta T1$  values had  
269 diverged markedly amongst participants, and were no longer statistically significantly different from  
270 0h values ( $p=0.093$  and  $0.829$  respectively) (Figure 2D).

271 In terms of circulating iron, plasma iron concentration rose sharply in all participants from a mean  
272 concentration of  $14.05 \pm 2.52$ uM at 0h to  $246.64 \pm 10.60$ uM at 3 hours ( $p<0.0001$ ), then declined to  
273  $22.01 \pm 1.14$ uM at 14 days and to  $22.23 \pm 2.31$ uM at 42 days such that plasma iron levels at these  
274 timepoints were no longer significantly higher than what they were at 0h ( $p=0.78$  and  $0.722$   
275 respectively) (Figure 2E).

276 Transferrin saturation (Tsat) rose sharply in all participants from  $16.74 \pm 3.65\%$  at 0h to full saturation  
277 at 3 hours ( $p<0.0001$ ), then declined to  $36.68 \pm 3.78\%$  at 14 days and  $44.82 \pm 4.12\%$  at 42 days, though  
278 it remained significantly higher than it was at 0h ( $p=0.0034$  and  $p<0.0001$  respectively) (Figure 2F).

279 Plasma NTBI levels rose sharply in all participants from being below detection (assay LLOD is  
280  $0.607$ uM) at 0h to  $14.16 \pm 1.87$ uM at 3 hours post FCM infusion ( $p<0.0001$ ), then declined at day 14 to



281 below the LLOD in all participants but one, such that the mean concentration at this timepoint was  
282  $0.102 \pm 0.073 \mu\text{M}$  at 14 days ( $p=0.999$  compared to 0h). At 42 days post infusion, NTBI levels were  
283 below the detection limit for all participants ( $>0.999$  compared to 0h) (Figure 2G).

284 The presence of labile iron entities such as NTBI generates peroxides which in turn react with  
285 susceptible molecules, including certain lipids. Plasma malondialdehyde (MDA), a biomarker of lipid  
286 peroxidation rose in all participants from a mean of  $1.908 \pm 0.0185 \mu\text{M}$  at 0h to  $2.007 \pm 0.0180 \mu\text{M}$  at 3  
287 hours ( $p < 0.0001$ ). They declined to  $1.886 \pm 0.005 \mu\text{M}$  at day 14 such that they were no longer different  
288 from 0h ( $p=0.7816$ ), and then declined further to  $1.858 \pm 0.010 \mu\text{M}$  at day 42 ( $p=0.0473$  relative to 0h)  
289 (Figure 2H)

290 In terms of plasma ferritin, mean levels were  $12.77 \pm 6.27 \mu\text{g/mL}$  at 0h and were not significantly  
291 different at 3 hours post infusion ( $8.925 \pm 5.08 \mu\text{g/mL}$ ,  $p=0.9983$ ). However, they rose to  $344 \pm 41.59$   
292  $\mu\text{g/mL}$  at 14 days ( $p < 0.0001$  relative 0h) and  $65.8 \pm 18.99 \mu\text{g/mL}$  at 42 days ( $p=0.0041$  relative to 0h)  
293 The decline in ferritin levels from day 14 to day 42 was significant ( $p=0.0029$ ) (Figure 2I).

294 We also assessed the levels of the iron homeostatic hormone hepcidin, which were at  
295  $2.12 \pm 1.139 \text{ ng/mL}$  at 0h, remaining unchanged at 3h ( $3.16 \pm 1.55 \text{ ng/mL}$ ,  $p=0.9923$ ) but rising  
296 significantly to  $15.9 \pm 4.27 \text{ ng/mL}$  at 14 days ( $p=0.0301$ ) and further still to  $23.93 \pm 5.05 \text{ ng/mL}$  at 42  
297 days ( $p=0.0004$ ) (Figure 2J).

298 Haematological parameters, including haemoglobin, haematocrit and mean corpuscular volume  
299 were all significantly improved at days 14 and 42 compared to 0h (Figure 2k-m).

300 These data demonstrate that following infusion of a standard dose of FCM in iron-deficient patients,  
301 the myocardium takes up iron quickly, within 3 hours, coinciding with maximal rises in serum iron  
302 availability, both transferrin and non-transferrin bound. The iron taken up within the first 3 hours is  
303 retained in the myocardium for at least 42 days, despite declining serum iron availability. This is in  
304 contrast to the spleen, where iron uptake is maximal at 14 days, subsequently declining by 42 days.  
305 Additionally, changes in plasma ferritin levels followed the pattern of changes in splenic iron.

### 306 **Ferric carboxymaltose treatment in mice results in rapid and sustained rise in myocardial labile** 307 **iron pool (LIP).**

308 Having observed an increase in myocardial iron following FCM infusion in patients, we sought to  
309 determine how this iron is handled in the myocardium. To that effect, we used iron-caged luciferin  
310 (ICL-1), which is only converted into the substrate of the cytoplasmic enzyme luciferase in the  
311 presence of cytoplasmic labile iron. This approach was used to quantitatively assess the impact on  
312 myocardial LIP of a single intravenous infusion of FCM ( $15 \text{ mg/kg}$  iron) into iron-replete or iron-  
313 deficient mice 1 hour or 42 days after infusion (Figure 3A). The iron status of mice was confirmed  
314 (supplemental Figure 2A, B).

315 In FCM-treated iron-deficient mice, myocardial LIP was raised both 1 hour after infusion ( $p=0.028$  vs  
316 saline) and 42 days after infusion ( $p=0.013$  vs saline) (Figure 3B). In FCM-treated iron-replete mice,  
317 myocardial LIP was raised 1 hour post infusion ( $p=0.035$  vs saline) and there was also a trend for the  
318 increase to be sustained 42 days after infusion ( $p=0.06$  saline vs FCM) (Figure 3B). Of note,  
319 myocardial LIP was lower in iron-deficient mice than in iron-replete mice ( $p=0.0047$ ) (Supplemental  
320 figure 2C)

321 As with patients, we sought to understand the pathways underpinning the rise in myocardial iron.  
322 FCM infusion into iron-deficient mice raised spleen iron within 1 hour ( $p=0.02$  relative to saline),  
323 through the rise was much more pronounced 42 days post infusion ( $p=0.004$  relative to saline). In

324 iron-replete mice, FCM infusion did not raise spleen iron after 1 hour, but did so after 42 days  
325 ( $p=0.015$  relative to saline) (Figure 3C). Changes in liver iron followed a similar trend as changes in  
326 spleen iron (Figure 3D). In terms of circulating iron availability, serum iron levels were raised by FCM  
327 infusion in comparison to saline in iron-deficient mice 1 hour after infusion ( $p<0.0001$  relative to  
328 saline), and were still raised 42 days post infusion ( $p=0.0002$  relative to saline). In iron-replete mice,  
329 serum iron levels were raised 1 hour after FCM infusion ( $p<0.0001$  relative to saline) but not  
330 significantly so 42 days after infusion ( $p=0.392$  relative to saline) (Figure 3E). Changes in transferrin  
331 saturation (Tsat) reflected changes in serum iron levels, with full or near full saturation seen 1 hour  
332 after FCM infusion (Figure 3F). Consistent with this, NTBI was below the detection limit in saline-  
333 treated mice, but rose markedly 1 hour after FCM infusion in both iron-deficient mice ( $p=0.0003$   
334 relative to saline) and iron-replete mice ( $p=0.019$  relative to saline). There was some residual NTBI  
335 42 days post FCM infusion in iron-deficient mice ( $p=0.016$  relative to saline) (Figure 3G).

336 FCM did not have an acute effect on serum ferritin in either iron-deficient or iron-replete mice, but  
337 raised serum ferritin in iron-deficient mice after 42 days ( $p=0.0155$  relative to saline) (supplemental  
338 figure 2D).

339 These preclinical data confirm the previous clinical observation that FCM results in a rapid and  
340 sustained increase in myocardial iron and further demonstrate that the iron taken up by the  
341 myocardium is in labile (reactive) form, and remains so for at least 42 days post treatment.

#### 342 **Exposure to ferric carboxymaltose raises cellular LIP in cardiac myocytes via NTBI transporters**

343 The rapid rise in myocardial iron following FCM infusion indicates direct myocardial uptake of iron  
344 from the circulation through a pathway that bypasses reticuloendothelial macrophages. To ascertain  
345 direct uptake and determine its route(s), we used the rat cardiac myocyte cell line H2C9, transfected  
346 via lentivirus, to express the luciferase transgene (Supplemental Figure 3). FCM was added to the  
347 growth media at a concentration of 0.25mg iron/mL to reflect a standard patient dose. To eliminate  
348 any confounding effects of iron from the growth media additive fetal bovine serum (FBS), cardiac  
349 myocytes were switched to FBS-free growth media two hours before and throughout exposure to  
350 FCM or saline (Figure 4A).

351 Compared to saline treatment, FCM in growth media raised cellular LIP in cardiac myocytes at 0.5h  
352 ( $p=0.039$  relative to saline) and 2h ( $p=0.0204$  relative to saline) (Figure 4B). Given that this rise  
353 occurred in the absence of FBS (the source of transferrin in growth media), we postulated that it was  
354 the result of NTBI uptake. To test this hypothesis, we determined the impact of efonidipine, an  
355 inhibitor of L-type and T-type calcium channels (LTCC and TTCC), and Ebselen, an inhibitor of the  
356 ferrous iron transporter divalent metal transporter DMT1. We found that Ebselen reduced  
357 ( $p=0.0372$  compared to FCM alone) and efonidipine completely prevented ( $p<0.0001$  compared to  
358 FCM alone) the rise in cardiac myocyte LIP (Figure 4C).

359 Consistent with this, NTBI was present in the supernatants of FCM-treated cells, being below the  
360 detection limit in the supernatants of saline-treated cells ( $p=0.0014$ ) (Figure 4D).

361 These data confirm that FCM treatment raises LIP in cardiac myocytes and further demonstrate this  
362 rise is due to the uptake of extracellular NTBI derived from FCM.

363

## 364 **Discussion**

365 While IV iron therapies have been suggested to raise the iron content of certain tissues, including  
366 the heart<sup>39</sup>, the mechanisms underlying this rise, and the ultimate fate of the iron that is taken up  
367 remained unknown. The present study addresses these unknowns in the context of the heart,  
368 through longitudinal assessment of changes in myocardial iron relative to changes in splenic, liver  
369 and circulating iron, and specific tracing, of cellular labile iron, the immediate product of iron uptake.

370 The key and novel finding of the present study is that the rise in myocardial iron following a standard  
371 dose of intravenous iron with FCM results from rapid and direct uptake of FCM-derived NTBI in the  
372 circulation. Indeed, in iron-deficient patients and in mice, myocardial iron content peaked within  
373 hours of FCM infusion, a timeframe that is too rapid to be attributed to the canonical pathway of  
374 FCM degradation by reticuloendothelial macrophages. Indeed, splenic iron in patients (closely  
375 followed by plasma ferritin levels), only peaked at 14 days post infusion, and began to decline by 42  
376 days post infusion, consistent with the initial uptake of FCM and subsequent release of iron into the  
377 circulation. Acute rises in circulating iron levels, including the appearance of NTBI in patients and in  
378 mice, and the presence of NTBI in the supernatants of FCM-treated cells demonstrate that ferric  
379 carboxymaltose complex releases some of its iron directly into the circulation and in quantities that  
380 are sufficient to alter the iron content of the myocardium. A previous pharmacokinetic study of  
381 intravenous iron formulations in healthy volunteers also detected acute rises in NTBI and estimated  
382 that 10-40% of the iron contained within FCM is released rapidly and directly into the circulation as  
383 NTBI<sup>24</sup>. In cultured cardiac myocytes, exposure to clinically relevant dose of FCM raised intracellular  
384 iron content in the absence of any macrophages, and in a manner that was primarily dependent on  
385 LTCC and/or TTCC, and to a lesser extent DMT1, recognised NTBI transporters that are abundantly  
386 expressed in the heart, and known to be responsible for iron-overload cardiomyopathy in  
387 thalassaemia and hemochromatosis<sup>25-27</sup>. While DMT1 is regulated by IRPs according to cellular iron  
388 needs, LTCCs and TTCCs are not regulated in this manner, continuing to take up iron into cells  
389 despite excess intracellular iron levels.

390 The second key and novel finding of the present study is that the iron taken up into the myocardium  
391 following FCM treatment remains in labile form for weeks. Specialised organs of iron handling, such  
392 as the spleen and liver, are characterised by high iron storage capacity and rapid iron turnover owing  
393 to abundant levels of ferritin and ferroportin respectively<sup>28,29,40</sup>. That iron taken up into the  
394 myocardium remains labile 42 days later, is consistent with the fact that the myocardium is not a  
395 specialised organ of iron handling, and has relatively limited capacity for iron storage and  
396 turnover<sup>28,29</sup>. Intriguingly, in the spleen and liver, other relaxation parameters T2 and T2\* echoed  
397 changes in T1, dropping significantly following FCM infusion, with maximal drops at 14 days post  
398 infusion (supplemental figure 4A-D). In contrast, changes in myocardial T2 and T2\* did not echo  
399 changes in myocardial T1 and diverged greatly between participants, with myocardial  $\Delta T2$  only  
400 trending towards a significant drop at 42 days post infusion ( $p=0.086$  compared to 0h) (supplemental  
401 figure 4E,F). The lack of concordance between myocardial relaxation parameters T1, T2 and T2\* is a  
402 well-recognised phenomenon<sup>41-43</sup>. T1 has been shown to have higher sensitivity than T2\* for  
403 detecting milder myocardial iron loading in thalassaemia patients, and may be better at resolving  
404 small increases following IV iron therapy<sup>41,42</sup>. Changes in relaxation parameters reflect microscopic  
405 inhomogeneity in the magnetic field, created by the distribution of iron inside cells. Unbound labile  
406 iron has a diffuse cytoplasmic distribution, in contrast to stored iron, where up to 4500 atoms of iron  
407 are clustered inside the 80 Å diameter cavity of the ferritin molecule<sup>43</sup>. Thus, it is likely that labile  
408 iron affects the magnetic field, and consequently relaxation parameters, differently from the stored  
409 iron. Our findings are consistent with the idea that T1 better reflects labile iron entities, while T2 and  
410 T2\* better reflect stored iron entities.

411 The findings of the current study have important clinical implications. The lack of iron clearance from  
412 the myocardium over the period of 42 days highlights the potential for cumulative build up with  
413 repeated doses. Based on the observed mean drop in myocardial T1 of -28.45ms after a single IV  
414 iron dose, calculations estimate that 6 doses would cumulatively lower myocardial T1 to below  
415 850ms, the cut-off shown to predict iron overload cardiomyopathy<sup>44</sup> (supplemental table 1). This  
416 raises pertinent questions about the safety of long-term IV iron therapy, increasingly being adopted  
417 in some patients, e.g. malabsorptive disorders, women with heavy uterine bleeding, chronic  
418 disorders<sup>45,46</sup>. Trials of long-term IV iron therapy in heart failure patients (where up to 9 doses were  
419 administered) have not reported an increased risk of adverse effects<sup>1, 47-49</sup>. However, myocardial iron  
420 content was not monitored in these studies, and any manifestation of cardiac iron toxicity could  
421 have been masked by the clinical signs of pre-existing heart failure. In these settings, minimum and  
422 maximum ferritin cut offs are often used to inform the need for further IV iron doses, and to  
423 safeguard against the risk of parenchymal iron overload respectively. However, our findings that  
424 myocardial iron uptake following IV iron therapy is independent of reticuloendothelial macrophages  
425 indicate that are also uncoupled from changes in plasma ferritin levels. Hence ferritin cut-offs may  
426 not be appropriate to safeguard against the risk of myocardial iron overload in patients on long term  
427 IV iron therapy, and MR based monitoring of myocardial iron should be considered instead.  
428 Additionally, in settings where myocardial iron repletion maybe desirable, the benefits sustained by  
429 patients would be independent of changes in plasma ferritin levels<sup>1</sup>.

#### 430 **Study limitations**

431 The clinical findings of the present study are derived from a relatively small number of participants.  
432 Most of these were women with iron deficiency due to heavy menstrual bleeding, and it remains to  
433 be determined if the study's findings can be generalised to patient groups with different aetiologies  
434 of iron deficiency. Though not specific to this study, the use of MR relaxometry to estimate tissue  
435 iron content has its limitations. For instance, relaxometry results depend on the choice of  
436 sequence and inferences on tissue iron content hinge on a gross simplification that the relaxivity  
437 coefficients for all/any iron species in blood and tissue are similar across all study visits<sup>50</sup>.

438 The pre-clinical findings of the present study rely on luminescence-based imaging of labile iron, with  
439 the main limitation that imaging is conducted on isolated hearts, to safeguard against interferences  
440 from surrounding tissues, including the epidermis and fur. Excision of the heart prior to LIP imaging  
441 has the potential to impact on luciferase enzyme activity and total luminescence signal, though this  
442 risk would have been present in all experimental groups.

#### 443 **Acknowledgements**

444 SL-L conceived project, secured funds, analysed data and wrote manuscript. PP and MD recruited  
445 patients. AS performed study procedures in participants. VF and SP designed MR imaging protocol  
446 and analysed MR data. MVA, KS, YL, CB, PB, PH, DS, HM performed experiments. All reviewed and  
447 commented on manuscript.

448 We are grateful to OCMR radiographers Dilliram Adhikari, Neil Fox, Joana Leal Pelado and Rebecca  
449 Mills for running MRI scans.

450 We are grateful to all the participants (and their families) who took part, without whom this study  
451 would not have been possible.

#### 452 **Funding**

453 S L-L is funded by the Medical Research Council (MR/ V009567/1/) and the British Heart Foundation  
454 Centre for Research Excellence HSR00031 and RE/18/3/34214. YL is funded by the British Heart  
455 Foundation Centre for Research RE/18/3/34214. CB is funded by the Wellcome Trust. AS is currently  
456 supported by a National Institute for Health and Care Research Academic Clinical Lectureship award.

#### 457 **Disclosure of interest**

458 S.L-L reports receipt of previous research funding from Vifor Pharma, personal honoraria on a  
459 lecture from Pharmacosmos and consultancy fees from Disc Medicine and ScholarRock. AS is an  
460 Editor of Anaesthesia.

#### 461 **Data availability statement**

462 Research data will be made available upon reasonable request.

#### 463 **References**

464

- 465 1. Lakhali-Littleton, S, Cleland JG. Iron deficiency and supplementation in heart failure. *Nature*  
466 *Reviews Cardiology*. In press
- 467 2. von Haehling S, Gremmler U, Krumm M, Mibach F, Schön N, Taggeselle J, et al. Prevalence  
468 and clinical impact of iron deficiency and anaemia among outpatients with chronic heart  
469 failure: The PrEP Registry. *Clin Res Cardiol*. 2017 Jun;106(6):436–43. doi:10.1007/s00392-  
470 016-1073-y
- 471 3. Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B, et al. Iron  
472 deficiency: an ominous sign in patients with systolic chronic heart failure. *Eur Heart J*. 2010  
473 Aug;31(15):1872–80. doi:10.1093/eurheartj/ehq158
- 474 4. Ghio A, Hilborn ED. Indices of iron homeostasis correlate with airway obstruction in an  
475 NHANES III cohort. *Int J Chron Obstruct Pulmon Dis*. 2017 Jul 18;12:2075–84.  
476 doi:10.2147/copd.s138457
- 477 5. Silverberg DS, Mor R, Tia Weu M, Schwartz D, Schwartz IF, Chernin G. Anemia and iron  
478 deficiency in COPD patients: prevalence and the effects of correction of the anemia with  
479 erythropoiesis stimulating agents and intravenous iron. *BMC Pulm Med*. 2014 Feb 24;14(1).  
480 doi:10.1186/1471-2466-14-24
- 481 6. Eisenga MF, Nolte IM, van der Meer P, Bakker SJL, Gaillard CAJM. Association of different  
482 iron deficiency cutoffs with adverse outcomes in chronic kidney disease. *BMC Nephrol*. 2018  
483 Sep 12;19(1). doi:10.1186/s12882-018-1021-3
- 484 7. Eisenga MF, Minović I, Berger SP, Kootstra-Ros JE, van den Berg E, Riphagen IJ, et al. Iron  
485 deficiency, anemia, and mortality in renal transplant recipients. *Transpl Int*. 2016  
486 Nov;29(11):1176–83. doi:10.1111/tri.12821
- 487 8. Crawford J, Cella D, Cleland CS, Cremieux P, Demetri GD, Sarokhan BJ, et al. Relationship  
488 between changes in hemoglobin level and quality of life during chemotherapy in anemic  
489 cancer patients receiving epoetin alfa therapy. *Cancer*. 2002 Aug 15;95(4):888–95.  
490 doi:10.1002/cncr.10763
- 491 9. Gasche C, Lomer MCE, Cavill I, Weiss G. Iron, anaemia, and inflammatory bowel diseases.  
492 *Gut*. 2004 Aug;53(8):1190–7. doi:10.1136/gut.2003.035758
- 493 10. Dignass AU, Gasche C, Bettenworth D, Birgegård G, Danese S, Gisbert JP, et al. European  
494 Consensus on the Diagnosis and Management of Iron Deficiency and Anaemia in  
495 Inflammatory Bowel Diseases. *J Crohns Colitis*. 2015 Mar;9(3):211–22. doi:10.1093/ecco-  
496 jcc/jju009



- 497 11. Vidal F, Gillibert A, Quillard M, Fardellone P, Vittecoq O, Lequerré T. Does iron deficiency  
498 contribute to fatigue in patients with rheumatoid arthritis without anemia? *Joint Bone*  
499 *Spine*. 2020 Jan;87(1):89. doi:10.1016/j.jbspin.2019.06.004
- 500 12. Fowler AJ, Ahmad T, Phull MK, Allard S, Gillies MA, Pearse RM. Meta-analysis of the  
501 association between preoperative anaemia and mortality after surgery. *Br J Surg*. 2015  
502 Oct;102(11):1314-24. doi: 10.1002/bjs.9861.
- 503 13. Low MSY, Speedy J, Styles CE, De-Regil LM, Pasricha S-R. Daily Iron Supplementation for  
504 improving anaemia, iron status and health in menstruating women. *Cochrane Database Syst*  
505 *Rev*. 2016 Apr 18;2016(4). doi:10.1002/14651858.cd009747.pub2
- 506 14. American Regent, Inc. Venofer Prescribing Information. Shirley, New York: American Regent,  
507 Inc.; 2022. Available from: [https://www.venofer.com/pdfs/venofer-prescribing-](https://www.venofer.com/pdfs/venofer-prescribing-information.pdf)  
508 [information.pdf](https://www.venofer.com/pdfs/venofer-prescribing-information.pdf)
- 509 15. Sanofi Aventis US. Ferrlecit Prescribing Information. Silver Spring, Maryland: Food and Drug  
510 Administration; 2022. Available from:  
511 [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2022/020955s020lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020955s020lbl.pdf)
- 512 16. Pharmacosmos Therapeutics Inc. MONOFERRIC Prescribing Information. Silver Spring,  
513 Maryland: Food and Drug Administration; 2022. Available from:  
514 [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2022/208171Orig1s002lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208171Orig1s002lbl.pdf)
- 515 17. American Regent, Inc. Injectafer Prescribing Information. Silver Spring, Maryland: Food and  
516 Drug Administration; 2023. Available from:  
517 [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2023/203565s024lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203565s024lbl.pdf)
- 518 18. Funk F, Flühmann B, Barton AE. Criticality of Surface Characteristics of Intravenous Iron–  
519 Carbohydrate Nanoparticle Complexes: Implications for Pharmacokinetics and  
520 Pharmacodynamics. *Int J Mol Sci*. 2022 Feb 15;23(4):2140. doi:10.3390/ijms23042140
- 521 19. Alphandéry E. Iron oxide nanoparticles for therapeutic applications. *Drug Discov Today*. 2020  
522 Jan;25(1):141–9. doi:10.1016/j.drudis.2019.09.020
- 523 20. Arami H, Khandhar A, Liggitt D, Krishnan KM. In vivo delivery, pharmacokinetics,  
524 biodistribution and toxicity of iron oxide nanoparticles. *Chem Soc Rev*. 2015 Dec  
525 7;44(23):8576–607. doi:10.1039/c5cs00541h
- 526 21. Rouault T, Klausner R. Regulation of iron metabolism in eukaryotes. *Current Topics in*  
527 *Cellular Regulation*. 1997 Jan 1;35:1–19. doi:10.1016/s0070-2137(97)80001-5
- 528 22. Cohen LA, Gutierrez L, Weiss A, Leichtmann-Bardoogo Y, Zhang D, Crooks DR, et al. Serum  
529 ferritin is derived primarily from macrophages through a nonclassical secretory pathway.  
530 *Blood*. 2010 Sep 2;116(9):1574–84. doi:10.1182/blood-2009-11-253815
- 531 23. Ferring-Appel D, Hentze MW, Galy B. Cell-autonomous and systemic context-dependent  
532 functions of iron regulatory protein 2 in mammalian iron metabolism. *Blood*. 2009 Jan  
533 15;113(3):679–87. doi:10.1182/blood-2008-05-155093
- 534 24. Garbowski MW, Bansal S, Porter JB, Mori C, Burckhardt S, Hider RC. Intravenous iron  
535 preparations transiently generate non-transferrin-bound iron from two proposed pathways.  
536 *Haematologica*. 2020 Nov 1;106(11):2885–96. doi:10.3324/haematol.2020.250803
- 537 25. Knutson MD. Non-transferrin-bound iron transporters. *Free Radic Biol Med*. 2019  
538 Mar;133:101–11. doi:10.1016/j.freeradbiomed.2018.10.413
- 539 26. Oudit GY, Sun H, Trivieri MG, Koch SE, Dawood F, Ackerley C, et al. L-type Ca<sup>2+</sup> channels  
540 provide a major pathway for iron entry into cardiomyocytes in iron-overload  
541 cardiomyopathy. *Nat Med*. 2003 Sep 1;9(9):1187–94. doi:10.1038/nm920
- 542 27. Kumfu S, Chattipakorn S, Chinda K, Fucharoen S, Chattipakorn N. T-type calcium channel  
543 blockade improves survival and cardiovascular function in thalassemic mice. *Eur J Haematol*.  
544 2012 Jun;88(6):535–48. doi:10.1111/j.1600-0609.2012.01779.x



- 545 28. Powell LW, Alpert E, Isselbacher KJ, Drysdale JW. Human Isoferritins: Organ Specific Iron and  
546 Apoferritin Distribution. *Br J Haematol.* 1975 May;30(1):47–55. doi:10.1111/j.1365-  
547 2141.1975.tb00516.x
- 548 29. Srivastava AK, Reutovich AA, Hunter NJ, Arosio P, Bou-Abdallah F. Ferritin  
549 microheterogeneity, subunit composition, functional, and physiological implications. *Sci Rep.*  
550 2023 Nov 14;13(1):19862. doi:10.1038/s41598-023-46880-9
- 551 30. Udani K, Chris-Olaiya A, Ohadugha C, Malik A, Sansbury J, Paari D. Cardiovascular  
552 manifestations in hospitalized patients with hemochromatosis in the United States. *Int J*  
553 *Cardiol.* 2021 Nov 1;342:117–24. doi:10.1016/j.ijcard.2021.07.060
- 554 31. Messroghli DR, Moon JC, Ferreira VM, Grosse-Wortmann L, He T, Kellman P, Mascherbauer  
555 J, Nezafat R, Salerno M, Schelbert EB, Taylor AJ, Thompson R, Ugander M, van Heeswijk RB,  
556 Friedrich MG. Clinical recommendations for cardiovascular magnetic resonance mapping of  
557 T1, T2, T2\* and extracellular volume: A consensus statement by the Society for  
558 Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for  
559 Cardiovascular Imaging (EACVI). *J Cardiovasc Magn Reson.* 2017 Oct 9;19(1):75. doi:  
560 10.1186/s12968-017-0389-8. Erratum in: *J Cardiovasc Magn Reson.* 2018 Feb 7;20(1):9.
- 561 32. Aron AT, Heffern MC, Lonergan ZR, Vander Wal MN, Blank BR, Spangler B, et al. In vivo  
562 bioluminescence imaging of labile iron accumulation in a murine model of *Acinetobacter*  
563 *baumannii* infection. *Proc Natl Acad Sci U S A.* 2017 Nov 28;114(48):12669–74.  
564 doi:10.1073/pnas.1708747114
- 565 33. Lagan J, Naish JH, Simpson K, Zi M, Cartwright EJ, Foden P, Morris J, Clark D, Birchall L,  
566 Caldwell J, Trafford A, Fortune C, Cullen M, Chaudhuri N, Fildes J, Sarma J, Schelbert EB,  
567 Schmitt M, Piper Hanley K, Miller CA. Substrate for the Myocardial Inflammation-Heart  
568 Failure Hypothesis Identified Using Novel USPIO Methodology. *JACC Cardiovasc Imaging.*  
569 2021 Feb;14(2):365-376. doi: 10.1016/j.jcmg.2020.02.001
- 570 34. Piechnik SK, Ferreira VM, Dall'Armellina E, Cochlin LE, Greiser A, Neubauer S, Robson MD.  
571 Shortened Modified Look-Locker Inversion recovery (ShMOLLI) for clinical myocardial T1-  
572 mapping at 1.5 and 3 T within a 9 heartbeat breathhold. *J Cardiovasc Magn Reson.* 2010 Nov  
573 19;12(1):69. doi: 10.1186/1532-429X-12-69.
- 574 35. Zhang Q, Werys K, Popescu IA, Biasioli L, Ntusi NAB, Desai M, Zimmerman SL, Shah DJ, Autry  
575 K, Kim B, Kim HW, Jenista ER, Huber S, White JA, McCann GP, Mohiddin SA, Boubertakh R,  
576 Chiribiri A, Newby D, Prasad S, Radjenovic A, Dawson D, Schulz-Menger J, Mahrholdt H,  
577 Carbone I, Rimoldi O, Colagrande S, Calistri L, Michels M, Hofman MBM, Anderson L, Broberg  
578 C, Andrew F, Sanz J, Bucciarelli-Ducci C, Chow K, Higgins D, Broadbent DA, Semple S, Hafyane  
579 T, Wormleighton J, Salerno M, He T, Plein S, Kwong RY, Jerosch-Herold M, Kramer CM,  
580 Neubauer S, Ferreira VM, Piechnik SK. Quality assurance of quantitative cardiac T1-mapping  
581 in multicenter clinical trials - A T1 phantom program from the hypertrophic cardiomyopathy  
582 registry (HCMR) study. *Int J Cardiol.* 2021 May 1;330:251-258. doi:  
583 10.1016/j.ijcard.2021.01.026.
- 584 36. Cao Y-A, Wagers AJ, Beilhack A, Dusich J, Bachmann MH, Negrin RS, et al. Shifting foci of  
585 hematopoiesis during reconstitution from single stem cells. *Proc Natl Acad Sci U S A.* 2004  
586 Jan 6;101(1):221–6. doi:10.1073/pnas.2637010100
- 587 37. Lakhali-Littleton S, Wolna M, Carr CA, Miller JJJ, Christian HC, Ball V, et al. Cardiac ferroportin  
588 regulates cellular iron homeostasis and is important for cardiac function. *Proc Natl Acad Sci*  
589 *U S A.* 2015 Mar 10;112(10):3164–9. doi:10.1073/pnas.1422373112
- 590 38. Jacobs EMG, Hendriks JCM, van Tits BLJH, Evans PJ, Breuer W, Liu DY, et al. Results of an  
591 international round robin for the quantification of serum non-transferrin-bound iron: Need

- 592 for defining standardization and a clinically relevant isoform. *Anal Biochem.* 2005 Jun  
593 15;341(2):241–50. doi:10.1016/j.ab.2005.03.008
- 594 39. Núñez J, Miñana G, Cardells I, Palau P, Llàcer P, Fàcila L, Almenar L, López-Lereu MP,  
595 Monmeneu JV, Amiguet M, González J, Serrano A, Montagud V, López-Vilella R, Valero E,  
596 García-Blas S, Bodí V, de la Espriella-Juan R, Lupón J, Navarro J, Górriz JL, Sanchis J, Chorro FJ,  
597 Comín-Colet J, Bayés-Genís A; Myocardial-IRON Investigators\* †. Noninvasive Imaging  
598 Estimation of Myocardial Iron Repletion Following Administration of Intravenous Iron: The  
599 Myocardial-IRON Trial. *J Am Heart Assoc.* 2020 Feb 18;9(4):e014254. doi:  
600 10.1161/JAHA.119.014254.
- 601 40. Nemeth E, Ganz T. Hepcidin-Ferroportin Interaction Controls Systemic Iron Homeostasis. *Int*  
602 *J Mol Sci.* 2021 Jun 17;22(12):6493. doi:10.3390/ijms22126493
- 603 41. Meloni A, Martini N, Positano V, De Luca A, Pistoia L, Sbragi S, et al. Myocardial iron overload  
604 by cardiovascular magnetic resonance native segmental T1 mapping: a sensitive approach  
605 that correlates with cardiac complications. *J Cardiovasc Magn Reson.* 2021 Jun 14;23(1):70.  
606 doi:10.1186/s12968-021-00765-w
- 607 42. Torlasco C, Cassinerio E, Roghi A, Faini A, Capecchi M, Abdel-Gadir A, et al. Role of T1  
608 mapping as a complementary tool to T2\* for non-invasive cardiac iron overload assessment.  
609 *PLoS One.* 2018 Feb 21;13(2):e0192890. doi:10.1371/journal.pone.0192890
- 610 43. Theil EC. Ferritin: the protein nanocage and iron biomineral in health and in disease. *Inorg*  
611 *Chem.* 2013;52(21):12223-12233. doi:10.1021/ic400484n
- 612 44. Singh SP, Jagia P, Ojha V, Seth T, Naik N, Ganga KP, et al. Diagnostic Value of T1 Mapping in  
613 Detecting Iron Overload in Indian Patients with Thalassemia Major: A Comparison with T2\*  
614 Mapping. *Indian Journal of Radiology and Imaging.* 2024;34(01):54–9. doi:10.1055/s-0043-  
615 1772467
- 616 45. Shand AW, Nassar N. Rapid increase in intravenous iron therapy for women of reproductive  
617 age in Australia. *Med J Aust.* 2021 Apr;214(6):285-285.e1. doi: 10.5694/mja2.50979.
- 618 46. Niepel D, Klag T, Malek NP, Wehkamp J. Practical guidance for the management of iron  
619 deficiency in patients with inflammatory bowel disease. *Therap Adv Gastroenterol.* 2018 Apr  
620 26;11:1756284818769074. doi: 10.1177/1756284818769074.
- 621 47. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, McDonagh T,  
622 Parkhomenko A, Tavazzi L, Levesque V, Mori C, Roubert B, Filippatos G, Ruschitzka F, Anker  
623 SD; CONFIRM-HF Investigators. Beneficial effects of long-term intravenous iron therapy with  
624 ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency†. *Eur*  
625 *Heart J.* 2015 Mar 14;36(11):657-68. doi: 10.1093/eurheartj/ehu385.
- 626 48. Kalra PR, Cleland JGF, Petrie MC, Thomson EA, Kalra PA, Squire IB, Ahmed FZ, Al-Mohammad  
627 A, Cowburn PJ, Foley P, Graham FJ, Japp AG, Lane RE, Lang NN, Ludman AJ, Macdougall  
628 IC, Pellicori P, Ray R, Robertson M, Seed A, Ford I; IRONMAN Study Group. Intravenous ferric  
629 derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an  
630 investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. *Lancet.*  
631 2022 Dec 17;400(10369):2199-2209. doi: 10.1016/S0140-6736(22)02083-9.
- 632 49. Mentz RJ, Garg J, Rockhold FW, Butler J, De Pasquale CG, Ezekowitz JA, Lewis GD, O'Meara E,  
633 Ponikowski P, Troughton RW, Wong YW, She L, Harrington J, Adamczyk R, Blackman N,  
634 Hernandez AF; HEART-FID Investigators. Ferric Carboxymaltose in Heart Failure with Iron  
635 Deficiency. *N Engl J Med.* 2023 Sep 14;389(11):975-986. doi: 10.1056/NEJMoa2304968.
- 636 50. Moon JC, Messroghli DR, Kellman P, Piechnik SK, Robson MD, Ugander M, Gatehouse PD,  
637 Arai AE, Friedrich MG, Neubauer S, Schulz-Menger J, Schelbert EB; Society for Cardiovascular  
638 Magnetic Resonance Imaging; Cardiovascular Magnetic Resonance Working Group of the  
639 European Society of Cardiology. Myocardial T1 mapping and extracellular volume

640 quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working  
641 Group of the European Society of Cardiology consensus statement. J Cardiovasc Magn  
642 Reson. 2013 Oct 14;15(1):92. doi: 10.1186/1532-429X-15-92.  
643

## 644 **Figure legends**

### 645 **Figure1- Trial profile**

646 **Figure 2- Ferric carboxymaltose treatment in patients results in rapid and sustained rise in**  
647 **myocardial iron.** A) Schematic of study design. B) Longitudinal changes from baseline (0h) in  
648 myocardial T1 ( $\Delta T1$ ) for each participant. C) Longitudinal changes from baseline in splenic T1 ( $\Delta T1$ )  
649 for each participant, D) Longitudinal changes from baseline in liver T1 ( $\Delta T1$ ) for each participant. Per-  
650 participant longitudinal assessments of plasma iron (E), transferrin saturation Tsat (F), plasma non-  
651 transferrin-bound iron NTBI (G), plasma lipid peroxidation marker MDA (H), plasma ferritin (I),  
652 plasma hepcidin (J), haemoglobin Hb (K), haematocrit HCT (L) and mean corpuscular volume MCV  
653 (M).


654 **Figure 3- Ferric carboxymaltose treatment in mice results in rapid and sustained rise in myocardial**  
655 **labile iron pool LIP.** A) Schematic of study design. ID=iron-deficient diet containing 5 parts per  
656 million (ppm) iron. RD=replete diet containing 200ppm iron. ICL-1=iron-caged luciferin. Luc Tg mice  
657 are transgenic for the luciferase gene. **B)** Average radiance in hearts of iron-deficient or iron replete  
658 mice 1 hour or 42 days after intravenous infusion of saline or FCM (15mg/kg iron). Representative  
659 luminescence images of hearts from each experimental group are also shown. **C)** Total elemental  
660 iron concentration in the spleen. D) Total elemental iron concentration in the liver. E) Concentrations  
661 of iron in serum, F) Transferrin saturation Tsat in serum, G) Concentrations of non-transferrin bound  
662 iron NTBI in serum.

663 **Figure 4- Exposure to Ferric carboxymaltose raises cellular LIP in cardiac myocytes via NTBI**  
664 **transporters.** A) Schematic of study design using rat cardiac myocytes, expressing the luciferase  
665 transgene . B) Average radiance in cardiac myocytes after 0.5h or 2h exposure to saline or FCM  
666 (0.25mg/ml iron) in growth media. Luminescence of individual wells are shown in bottom panel. C)  
667 Average radiance in cardiac myocytes after 1h exposure to saline, FCM (0.25mg/ml iron) alone, or in  
668 combination with ebselen (DMT1 inhibitor) or efonidipine (L-type and T-type calcium channel  
669 inhibitor). Luminescence of individual wells are shown in bottom panel D) NTBI concentration in  
670 supernatants of cells exposed to saline or FCM (0.25mg/ml).


671

# GRAPHICAL ABSTRACT


## CANONICAL PATHWAY




## NON-CANONICAL PATHWAY




**Figure 1**



# Figure 2





**Figure 3**

**Figure 4**